These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 18455893

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Evaluation of carboxymethyl-beta-cyclodextrin with acid function: improvement of chemical stability, oral bioavailability and bitter taste of famotidine.
    Mady FM, Abou-Taleb AE, Khaled KA, Yamasaki K, Iohara D, Taguchi K, Anraku M, Hirayama F, Uekama K, Otagiri M.
    Int J Pharm; 2010 Sep 15; 397(1-2):1-8. PubMed ID: 20600734
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Evaluation of Chlorpheniramine Maleate microparticles in orally disintegrating film and orally disintegrating tablet for pediatrics.
    Lou H, Liu M, Qu W, Hu Z, Brunson E, Johnson J, Almoazen H.
    Drug Dev Ind Pharm; 2014 Jul 15; 40(7):910-8. PubMed ID: 23621768
    [Abstract] [Full Text] [Related]

  • 6. Taste-masking effect of physical and organoleptic methods on peppermint-scented orally disintegrating tablet of famotidine based on suspension spray-coating method.
    Sugiura T, Uchida S, Namiki N.
    Chem Pharm Bull (Tokyo); 2012 Jul 15; 60(3):315-9. PubMed ID: 22382410
    [Abstract] [Full Text] [Related]

  • 7. Formulation and optimization of orally disintegrating tablets of sumatriptan succinate.
    Sheshala R, Khan N, Darwis Y.
    Chem Pharm Bull (Tokyo); 2011 Jul 15; 59(8):920-8. PubMed ID: 21804234
    [Abstract] [Full Text] [Related]

  • 8. In vitro and in vivo correlation of disintegration and bitter taste masking using orally disintegrating tablet containing ion exchange resin-drug complex.
    Kim JI, Cho SM, Cui JH, Cao QR, Oh E, Lee BJ.
    Int J Pharm; 2013 Oct 15; 455(1-2):31-9. PubMed ID: 23933050
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. In vitro and in vivo investigation of taste-masking effectiveness of Eudragit E PO as drug particle coating agent in orally disintegrating tablets.
    Drašković M, Medarević D, Aleksić I, Parojčić J.
    Drug Dev Ind Pharm; 2017 May 15; 43(5):723-731. PubMed ID: 27494420
    [Abstract] [Full Text] [Related]

  • 13. Design and evaluation of taste masked dextromethorphan hydrobromide oral disintegrating tablets.
    Malladi M, Jukanti R, Nair R, Wagh S, Padakanti HS, Mateti A.
    Acta Pharm; 2010 Sep 15; 60(3):267-80. PubMed ID: 21134862
    [Abstract] [Full Text] [Related]

  • 14. Enhancement of the aqueous solubility and masking the bitter taste of famotidine using drug/SBE-beta-CyD/povidone K30 complexation approach.
    Mady FM, Abou-Taleb AE, Khaled KA, Yamasaki K, Iohara D, Ishiguro T, Hirayama F, Uekama K, Otagiri M.
    J Pharm Sci; 2010 Oct 15; 99(10):4285-94. PubMed ID: 20737636
    [Abstract] [Full Text] [Related]

  • 15. The prediction of the palatability of orally disintegrating tablets by an electronic gustatory system.
    Nakamura H, Uchida S, Sugiura T, Namiki N.
    Int J Pharm; 2015 Sep 30; 493(1-2):305-12. PubMed ID: 26216412
    [Abstract] [Full Text] [Related]

  • 16. Preparation and evaluation of orally disintegrating tablets of taste masked phencynonate HCl using ion-exchange resin.
    Ge Z, Yang M, Wang Y, Shan L, Gao C.
    Drug Dev Ind Pharm; 2015 Jun 30; 41(6):934-41. PubMed ID: 24785576
    [Abstract] [Full Text] [Related]

  • 17. A novel and discriminative method of in vitro disintegration time for preparation and optimization of taste-masked orally disintegrating tablets of carbinoxamine maleate.
    Liu Y, Li P, Qian R, Sun T, Fang F, Wang Z, Ke X, Xu B.
    Drug Dev Ind Pharm; 2018 Aug 30; 44(8):1317-1327. PubMed ID: 29521132
    [Abstract] [Full Text] [Related]

  • 18. Formulation, development, and performance evaluation of metoclopramide HCl oro-dispersible sustained release tablet.
    Kasliwal N, Negi JS, Jugran V, Jain R.
    Arch Pharm Res; 2011 Oct 30; 34(10):1691-700. PubMed ID: 22076769
    [Abstract] [Full Text] [Related]

  • 19. Enhancement of famotidine dissolution rate through liquisolid tablets formulation: in vitro and in vivo evaluation.
    Fahmy RH, Kassem MA.
    Eur J Pharm Biopharm; 2008 Aug 30; 69(3):993-1003. PubMed ID: 18396390
    [Abstract] [Full Text] [Related]

  • 20. [Dissolution rate and bioavailability of famotidine tablets].
    Lu B, He YJ, Guo P, Ye LM.
    Yao Xue Xue Bao; 1992 Aug 30; 27(4):303-7. PubMed ID: 1442047
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.